Emerging drugs for obesity therapy

Area of Science:

• Cardiovascular disease
• Metabolic disorders
• Pharmacology

Background:

• Central obesity is a significant risk factor for cardiovascular disease (CV) development, contributing to dyslipidemia, glucose intolerance, insulin resistance, and hypertension.
• CV disease remains a leading cause of mortality worldwide.
• Current obesity therapies, including diet and lifestyle changes, often yield modest weight loss and poor long-term adherence.

Purpose of the Study:

• To review the therapeutic potential of novel antiobesity molecules.
• To analyze drug development based on neuroendocrine mechanisms regulating body weight.
• To assess strategies for reducing CV risk and mortality associated with obesity.

Main Methods:

• Review of current literature on antiobesity agents.
• Analysis of neuroendocrine pathways involved in energy homeostasis.
• Evaluation of molecular targets for novel drug development.

Main Results:

• Existing antiobesity drugs like orlistat and sibutramine demonstrate limited efficacy, typically achieving 5-10% weight loss.
• Rimonabant, a cannabinoid-1 receptor antagonist, showed effectiveness in weight loss and metabolic risk factor improvement but was withdrawn due to safety concerns (suicidality, seizures).
• Emerging research into neuroendocrine mechanisms offers promising molecular targets for next-generation antiobesity drugs.

Conclusions:

• Novel antiobesity drugs targeting energy homeostasis are needed to address the limitations of current therapies.
• Further research into molecular targets is crucial for developing effective and safe obesity treatments.
• Reducing obesity-related CV risk and mortality requires innovative pharmacological approaches.